

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 235 826 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
03.09.2003 Bulletin 2003/36

(51) Int Cl.7: **C07D 453/02, C07D 451/04,
A61K 31/439, A61K 31/46,
A61P 25/00**

(21) Application number: **00971959.2**

(86) International application number:
PCT/SE00/01993

(22) Date of filing: **13.10.2000**

(87) International publication number:
WO 01/029034 (26.04.2001 Gazette 2001/17)

(54) **QUINUCLIDINE ACRYLAMIDES**

CHINUCLIDIN-ACRYLAMIDE

ACRYLAMIDES DE QUINUCLIDINE

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(56) References cited:
**EP-A2- 0 581 165 WO-A1-94/20465
WO-A1-96/21644 WO-A1-98/01443**

(30) Priority: **18.10.1999 SE 9903760**

(43) Date of publication of application:
04.09.2002 Bulletin 2002/36

(73) Proprietor: **AstraZeneca AB
151 85 Södertälje (SE)**

• **DATABASE CAPLUS [Online] DOC. NO. 124:649
KOSTOCHKA L.M. ET AL.: 'Synthesis and
local-anesthetic activity of tropane enamides
and amides' Retrieved from STN International
Database accession no. 1995:904880 &
KHIM.-FARM. ZH. vol. 29, no. 3, 1995, pages 40 -
42**

(72) Inventor: **SCHMIESING, Richard AstraZeneca US
Wilmington, DE 19850 (US)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 235 826 B1

Description**Technical Field**

[0001] This invention relates to novel quinuclidine acrylamides or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. A further object is to provide active compounds that are potent ligands for nicotinic acetylcholine receptors (nAChRs).


Background of the Invention

[0002] The use of compounds which bind nicotinic acetylcholine receptors in the treatment of a range of disorders involving reduced cholinergic function such as Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, neuroprotection, schizophrenia, analgesia, Tourette's syndrome, and Parkinson's disease has been discussed in McDonald et al. (1995) "Nicotinic Acetylcholine Receptors: Molecular Biology, Chemistry and Pharmacology", Chapter 5 in Annual Reports in Medicinal Chemistry, vol. 30, pp. 41-50, Academic Press Inc., San Diego, CA; and in Williams et al. (1994) "Neuronal Nicotinic Acetylcholine Receptors," Drug News & Perspectives, vol. 7, pp. 205-223.





[0003] Quinuclidine acrylamide derivatives as potential antitussive agents are known in the art, in EP-A2-581,165. Indole derivatives are known in the art, e.g. in WO94/20465.

Disclosure of the Invention


[0004] According to the invention it has been found that compounds of formula I, wherein:



A represents:



or



R represents hydrogen or methyl;

R¹ and R² are independently hydrogen, or C₁-C₄ alkyl;

R³ and R⁴ are independently hydrogen, C₁-C₄ alkyl or SAR, provided that at least one of R³ and R⁴ represents SAR;

Ar represents a 5- or 6-membered aromatic or heteroaromatic ring containing zero to three nitrogen atoms, zero or one oxygen atom, and zero or one sulfur atom or an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atom, and zero to one sulfur atom which may optionally be substituted with one or more substituents selected from: hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, aryl, heteroaryl, -CO₂R⁵, -CN, -NO₂, -NR⁶R⁷; -CF₃, -OR⁸;

R⁵, R⁶, R⁷, and R⁸ are independently hydrogen, C₁-C₄ alkyl, aryl, heteroaryl, -C(O)R⁹, -C(O)NHR¹⁰, -C(O)R¹¹, -SO₂R¹², or,

R⁶ and R⁷ may together be (CH₂)_jQ(CH₂)_k where Q is O, S, NR¹³, or, a bond;

j is 2 to 7;

k is 0 to 2;

R⁹, R¹⁰, R¹¹, R¹², and R¹³, are independently C₁-C₄ alkyl, aryl, or heteroaryl; or an enantiomer thereof, and the pharmaceutically acceptable salts thereof are potent ligands for nicotinic acetylcholine receptors.

[0005] Unless otherwise indicated, the C₁-C₄ alkyl groups referred to herein, e.g., methyl, ethyl, n-propyl, n-butyl, i-propyl, i-butyl, t-butyl, s-butyl, whether alone or part of another group, may be straight-chained or branched, and the C₃-C₄ alkyl groups may also be cyclic, e.g., cyclopropyl, cyclobutyl.


[0006] Unless otherwise indicated, aryl refers to a phenyl ring which may optionally be substituted with one to three of the following substituents chosen from among the following: halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, CO₂R⁷, -CN, -NO₂, -NR⁸R⁹, -CF₃, -OR¹⁰.

[0007] Unless otherwise indicated, heteroaryl refers to a 5- or 6-membered aromatic or heteroaromatic ring containing zero to three nitrogen atoms, zero or one oxygen atom, and zero or one sulfur atom, provided that the ring contains at least one nitrogen, oxygen, or sulfur atom, which may optionally be substituted with one or more substituents chosen from among the following: halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, CO₂R⁵, -CN, -NO₂, -NR⁶R⁷, -CF₃, -OR⁸.

[0008] Unless otherwise indicated, halogen refers to fluorine, chlorine, bromine, or iodine.

[0009] Pharmaceutically acceptable derivatives include solvates and salts. For example, the compounds of formula I can form acid addition salts with acids, such as the conventional pharmaceutically acceptable acids, for example, maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulfonic acids.

[0010] In a preferred embodiment of this aspect of the invention, is compound according to formula I, wherein A represents:



II

or an enantiomer thereof, and the pharmaceutically acceptable salts thereof.

[0011] Preferred compounds of the invention include compounds of formula I wherein R¹, R², and one of R³ or R⁴ are hydrogen;

[0012] Preferred compounds of the invention further comprise compounds of formula I wherein Ar represents a 5- or 6-membered aromatic or heteroaromatic ring containing zero to three nitrogen atoms, zero or one oxygen atom, and zero or one sulfur atom, including phenyl, 2-pyridyl, or 2-pyrimidinyl, any of which may optionally be substituted with one or more substituents chosen from among the following: hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, -CO₂R⁵, -CN, -NO₂, -NR⁶R⁷, -CF₃, -OR⁸.

[0013] Preferred compounds of the invention further comprise compounds of formula I wherein Ar is an heteroaromatic ring.

[0014] Preferred compounds of the invention further comprise compounds of formula I wherein Ar is a 6-membered aromatic or heteroaromatic ring, containing zero to two nitrogen atoms.

[0015] Preferred compounds of the invention include the following:

N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)propenamide] hydrochloride;
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-methylphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-methylphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-methylphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-methylphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methylphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methylphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-methoxyphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-methoxyphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-methoxyphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-methoxyphenylthio)propenamide];

N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methoxyphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methoxyphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyridylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-pyridylthio)propenamide];
5 *N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-pyridylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-pyridylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyrimidinylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-pyrimidinylthio)propenamide];
10 *N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methyl-3-furanylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methyl-3-furanylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-imidazolylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)-3-(methyl)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzothiazolylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-benzothiazolylthio)propenamide];
15 *N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(1-methyl-2-imidazolylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(1-methyl-2-imidazolylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamide];
20 *N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-chlorophenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thienylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-thienylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzoxazolylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-benzoxazolylthio)propenamide];
25 *N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-trifluoromethyl-2-pyrimidinylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-fluorophenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-fluorophenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolo[4,5-b]pyridylthio)propenamide];
30 *(R)*-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-thiazolo[4,5-b]pyridylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-fluorophenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-fluorophenylthio)propenamide];

or an enantiomer thereof, and the pharmaceutically acceptable salts thereof

[0016] Particularly preferred compounds of the invention include the following:

(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)propenamide] hydrochloride;
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-methylphenylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-methylphenylthio)propenamide];
40 *(R)*-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-methylphenylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-methylphenylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methylphenylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methylphenylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-methoxyphenylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-methoxyphenylthio)propenamide];
45 *(R)*-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-methoxyphenylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-methoxyphenylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methoxyphenylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methoxyphenylthio)propenamide];
50 *(R)*-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyridylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-pyridylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-pyridylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-pyridylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyrimidinylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-pyrimidinylthio)propenamide];
55 *(R)*-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methyl-3-furanylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methyl-3-furanylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-imidazolylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)-3-(methyl)propenamide];

(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzothiazolylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-benzothiazolylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(1-methyl-2-imidazolylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(1-methyl-2-imidazolylthio)propenamide];
5 *(R)*-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-chlorophenylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolylthio)propenamide];
10 *(R)*-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thienylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-thienylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzoxazolylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-benzoxazolylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-trifluoromethyl-2-pyrimidinylthio)propenamide];
15 *(R)*-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-fluorophenylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-fluorophenylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolo[4,5-b]pyridylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-thiazolo[4,5-b]pyridylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-fluorophenylthio)propenamide];
20 *(R)*-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-fluorophenylthio)propenamide];

or an enantiomer thereof, and the pharmaceutically acceptable salts thereof.


[0017] Further particularly preferred compounds of the invention includes:

(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyridylthio)propenamide];
25 *(R)*-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-pyridylthio)propenamide];
(R)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyrimidinylthio)propenamide];

or an enantiomer thereof, and the pharmaceutically acceptable salts thereof.

30 Methods of Preparation

[0018] In the reaction schemes and text that follow, R¹, R², R³ and R⁴, unless otherwise indicated, are as defined above for formula VII. The compounds of formula VII may be prepared according to the methods outlined in Scheme 1.



50 **Scheme 1**

[0019] Compounds of formula I may be prepared from compounds of formula II by reaction with a compound of formula III, wherein X represents a suitable leaving group, using a suitable acylation procedure.


[0020] Suitable leaving groups X include: OH, halogen, OAlkyl, OAryl, OCOAlkyl, OCOAryl, azide. A suitable acylation procedure involves treatment of a compound of formula II with a compound of formula III at 0-120 °C in a suitable solvent. The presence of a base, or, when X=OH, a coupling agent, may also be necessary for the reaction to occur.

Suitable bases for the reaction include: 4-(*N,N*-dimethylamino)pyridine, pyridine, triethylamine, *N,N*-diisopropylethylamine. The preferred base is *N,N*-diisopropylethylamine. Suitable coupling agents when X=OH include: carbodiimides, for example 1,3-dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; phosphonium reagents, for example benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate or benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate; and uronium reagents, for example O-benzotriazol-1-yl-*N,N,N',N'*-tetramethyluronium tetrafluoroborate. The preferred coupling agent is O-benzotriazol-1-yl-*N,N,N',N'*-tetramethyluronium tetrafluoroborate. Suitable solvents for the reaction include *N,N*-dimethylformamide, dimethylsulfoxide, tetrahydrofuran, or chloroform. The preferred solvent is *N,N*-dimethylformamide. The reaction is preferably performed at a temperature of 0-50 °C, and most preferably at a temperature of 20-30 °C.

[0021] Compounds of formula II in which R² represents an alkyl group may be prepared from compounds of formula II in which R² represents hydrogen by a suitable alkylation procedure.

[0022] Typical alkylation procedures include treatment with an appropriate alkyl halide or sulfonate ester and base, for example sodium hydride, in a suitable solvent, for example DMF, or reductive alkylation using the appropriate aldehyde or ketone together with a suitable reducing agent in an inert solvent. The preferred method is reductive alkylation. Suitable reducing agents include sodium borohydride and sodium cyanoborohydride. The preferred reducing agent is sodium borohydride. Suitable inert solvents include water, methanol or ethanol. The preferred solvent is methanol. The reaction is usually conducted at a temperature of 0 °C to 100 °C, preferably from 20 °C to 65 °C.

[0023] Compounds of formula II and III are either commercially available, or may be prepared by methods known to one skilled in the art. For example compound III may be prepared as shown in Scheme 2 according to the method described by G. Joshi, et al., Chemistry and Industry, (1991), 281.



III

Scheme 2

[0024] Use of compounds II and III as intermediates in a synthesis of a ligand for nicotinic acetylcholine receptors is another aspect of the invention.

[0025] Where necessary, hydroxy, amino, or other reactive groups may be protected using a protecting group as described in the standard text "Protecting groups in Organic Synthesis", 3rd Edition (1999) by Greene and Wuts.

[0026] The above described reactions, unless otherwise noted, are usually conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere). Unless otherwise stated, the above-described reactions are conducted under an inert atmosphere, preferably under a nitrogen atmosphere.

[0027] The compounds of the invention and intermediates may be isolated from their reaction mixtures by standard techniques.

[0028] Acid addition salts of the compounds of formula I which may be mentioned include salts of mineral acids, for example the hydrochloride and hydrobromide salts; and salts formed with organic acids such as formate, acetate, maleate, benzoate, tartrate, and fumarate salts.

[0029] Acid addition salts of compounds of formula I may be formed by reacting the free base or a salt, enantiomer or protected derivative thereof, with one or more equivalents of the appropriate acid. The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, e.g., water, dioxane, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed in vacuum or by freeze drying. The reaction may be a metathetical process or it may be carried out on an ion exchange resin.

[0030] The compounds of formula I exist in tautomeric or enantiomeric forms, all of which are included within the scope of the invention. The various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, e.g. fractional crystallization, or chiral HPLC. Alternatively the individual enantiomers may be made by reaction of the appropriate optically active starting materials under reaction conditions which will not cause racemization.

Pharmaceutical Compositions

[0031] A further aspect of the invention relates to a pharmaceutical composition for treating or preventing a condition or disorder as exemplified below arising from dysfunction of nicotinic acetylcholine receptor neurotransmission in a mammal, preferably a human, comprising an amount of a compound of formula I, an enantiomer thereof and/or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and an inert pharmaceutically acceptable carrier.

[0032] For the above-mentioned uses the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results will be obtained when the compounds of the invention are administered at a daily dosage of from about 0.1 mg to about 20 mg per kg of mammalian body weight, preferably given in divided doses 1 to 4 times a day or in sustained release form. For man, the total daily dose is in the range of from 5 mg to 1,400 mg, more preferably from 10 mg to 100 mg, and unit dosage forms suitable for oral administration comprise from 2 mg to 1,400 mg of the compound admixed with a solid or liquid pharmaceutical carrier or diluent.

[0033] The compounds of formula I or an enantiomer thereof and/or pharmaceutically acceptable salts thereof, may be used on their own or in the form of appropriate medicinal preparations for enteral, parenteral, oral, rectal or nasal administration. According to a further aspect of the invention, there is provided a pharmaceutical composition preferably comprising less than 80% and more preferably less than 50% by weight of a compound of the invention in admixture with an inert pharmaceutically acceptable diluent or carrier.

[0034] Examples of suitable diluents and carriers are:

- for tablets and dragees: lactose, starch, talc, stearic acid; for capsules: tartaric acid or lactose;
- for injectable solutions: water, alcohols, glycerin, vegetable oils; for suppositories: natural or hardened oils or waxes.

[0035] There is also provided a process for the preparation of such a pharmaceutical composition which comprises mixing the ingredients simultaneously or sequentially.

Utility

[0036] A further aspect of the invention is the use of a compound according to the invention, an enantiomer thereof or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of one of the below mentioned diseases or conditions; and a method of treatment or prophylaxis of one of the below mentioned diseases or conditions, which comprises administering a therapeutically effective amount of a compound according to the invention, or an enantiomer thereof or a pharmaceutically acceptable salt thereof, to a patient.

[0037] Compounds according to the invention are agonists of nicotinic acetylcholine receptors. While not being limited by theory, it is believed that agonists of the $\alpha 7$ nAChR (nicotinic acetylcholine receptor) subtype should be useful in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders, and have advantages over compounds which are or are also agonists of the $\alpha 4$ nAChR subtype. Therefore, compounds which are selective for the $\alpha 7$ nAChR subtype are preferred. The compounds of the invention are selective for the $\alpha 7$ nAChR subtype. The compounds of the invention are intended as pharmaceuticals, in particular in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders. Examples of psychotic disorders include schizophrenia, mania and manic depression, and anxiety. Examples of intellectual impairment disorders include Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, and Attention Deficit Hyperactivity Disorder. The compounds of the invention may also be useful as analgesics in the treatment of pain (including chronic pain) and in the treatment or prophylaxis of Parkinson's disease, Huntington's disease, Tourette's syndrome, and neurodegenerative disorders in which there is loss of cholinergic synapses. The compounds may further be indicated for the treatment or prophylaxis of jetlag, for use in inducing the cessation of smoking, and for the treatment or prophylaxis of nicotine addiction (including that resulting from exposure to products containing nicotine).

[0038] It is also believed that compounds according to the invention are useful in the treatment and prophylaxis of ulcerative colitis.

Pharmacology

[0039] The pharmacological activity of the compounds of the invention may be measured in the tests set out below:

Test A - Assay for affinity at $\alpha 7$ nAChR subtype

[0040] 125 I- α -Bungarotoxin (BTX) binding to rat hippocampal membranes. Rat hippocampi were homogenized in 20 volumes of cold homogenization buffer (HB: concentrations of constituents (mM): tris(hydroxymethyl)aminomethane 50; MgCl₂ 1; NaCl 120; KCl 5; pH 7.4). The homogenate was centrifuged for 5 minutes at 1000 g, the supernatant was saved and the pellet re-extracted. The pooled supernatants were centrifuged for 20 minutes at 12,000 x g, washed, and resuspended in HB. Membranes (30-80 μ g) were incubated with 5 nM [125 I] α -BTX, 1 mg/mL BSA (bovine serum albumin), test drug, and either 2 mM CaCl₂ or 0.5 mM EGTA [ethylene glycol-bis(β -aminoethylether)] for 2 hours at 21 °C, and then filtered and washed 4 times over Whatman glass fibre filters (thickness C) using a Brandel cell harvester. Pretreating the filters for 3 hours with 1% (BSA/0.01% PEI (polyethylenimine)) in water was critical for low filter blanks (0.07% of total counts per minute). Nonspecific binding was described by 100 μ M (-)-nicotine, and specific binding was typically 75%.

Test B - Assay for affinity to the $\alpha 4$ nAChR subtype

[0041] [3 H]-(-)-nicotine binding. Using a procedure modified from Martino-Barrows and Kellar (Mol Pharm (1987) 31: 169-174), rat brain (cortex and hippocampus) was homogenized as in the [125 I] α -BTX binding assay, centrifuged for 20 minutes at 12,000 x g, washed twice, and then resuspended in HB containing 100 μ M diisopropyl fluorophosphate. After 20 minutes at 4 °C, membranes (approximately 0.5 mg) were incubated with 3 nM [3 H]-(-)-nicotine, test drug, 1 μ M atropine, and either 2 mM CaCl₂ or 0.5 mM EGTA for 1 hour at 4 °C, and then filtered over Whatman glass fibre filters (thickness C) (pretreated for 1 hour with 0.5% PEI) using a Brandel cell harvester. Nonspecific binding was described by 100 μ M carbachol, and specific binding was typically 84%.

Binding data analysis for Tests A and B

[0042] IC₅₀ values and pseudo Hill coefficients (n_H) were calculated using the non-linear curve fitting program ALLFIT (DeLean A, Munson P J and Rodbard D (1977) Am. J. Physiol., 235:E97-E102). Saturation curves were fitted to a one site model, using the non-linear regression program ENZFITTER (Leatherbarrow, R.J. (1987)), yielding K_D values of 1.67 and 1.70 nM for the 125 I- α -BTX and [3 H]-(-)-nicotine ligands respectively. K_i values were estimated using the general Cheng-Prusoff equation:

$$K_i = [IC_{50}] / ((2 + ([ligand]/K_D)^n)^{1/n} - 1)$$

where a value of $n=1$ was used whenever $n_H < 1.5$ and a value of $n=2$ was used when $n_H \geq 1.5$. Samples were assayed in triplicate and were typically $\pm 5\%$. K_i values were determined using 6 or more drug concentrations. The compounds of the invention are compounds with binding affinities (K_i) of less than 1000 nM in either Test A or Test B, indicating that they are expected to have useful therapeutic activity.

General Experimental Procedures

[0043] Commercial reagents were used without further purification. Mass spectra were recorded using either a Hewlett Packard 5988A or a MicroMass Quattro-1 Mass Spectrometer and are reported as m/z for the parent molecular ion. Room temperature refers to 20-25°C.

Examples

[0044] The following examples are preferred non-limiting examples embodying preferred aspects of the invention.

Example 1

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)propenamide] hydrochloride

[0045] To a stirred solution of (R)-1-Aza-bicyclo[2.2.2]oct-3-ylamine dihydrochloride (25 g, 0.125 mol), 3-(phenylthio)acrylic acid (23.5 g, 0.13 mol), and diisopropylethylamine (90 ml) in dry DMF (600 ml) at ambient temperature was added in succession 1-hydroxybenzotriazole hydrate (17 g, 0.126 mol) and O-benzotriazol-1-yl-N,N',N'-tetramethyluronium tetrafluoroborate (40 g, 0.124 mol). The resulting amber-colored solution was stirred overnight, diluted with water (1 vol), and extracted with ether (2x700 ml). The aqueous phase was made basic (pH 10) with 50% aqueous

EP 1 235 826 B1

sodium hydroxide and extracted with chloroform (3x700 ml). The chloroform extracts were combined, washed with water, brine, dried over sodium sulfate and concentrated to dryness to give crude product as a syrup (40 g). The syrup was taken in isopropanol (1L), made acidic with gaseous HCL, and allowed to stand. The resulting solid was collected by filtration, recrystallized from isopropanol (2x), and dried in vacuo to give the title compound (8 g) as a white solid.

MS (ES⁺) 289. (MH⁺).

[0046] Purification of the mother liquors from above by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent gave (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(phenylthio)propenamide]; MS (ES⁺) 289. (MH⁺).

Example 2

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-methylphenylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-methylphenylthio)propenamide]

[0047] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(4-methylphenylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES⁺) 303. (MH⁺).

Example 3

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-methylphenylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-methylphenylthio)propenamide]

[0048] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(3-methylphenylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES⁺) 303. (MH⁺).

Example 4

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methylphenylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methylphenylthio)propenamide]

[0049] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(2-methylphenylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES⁺) 303. (MH⁺).

Example 5

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-methoxyphenylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-methoxyphenylthio)propenamide]

[0050] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(4-methoxyphenylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES⁺) 319. (MH⁺).

Example 6

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-methoxyphenylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-methoxyphenylthio)propenamide]

[0051] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(3-methoxyphenylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES⁺) 319. (MH⁺).

Example 7

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methoxyphenylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methoxyphenylthio)propenamide]

[0052] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(2-methoxyphenylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES⁺) 319. (MH⁺).

Example 8

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyridylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-pyridylthio)propenamide]

[0053] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(2-pyridylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES⁺) 290. (MH⁺).

Example 9

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-pyridylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-pyridylthio)propenamide]

[0054] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(4-pyridylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES⁺) 290. (MH⁺).

Example 10

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyrimidinylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-pyrimidinylthio)propenamide]

[0055] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(2-pyrimidinylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES⁺) 291. (MH⁺).

Example 11

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methyl-3-furanylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methyl-3-furanylthio)propenamide]

[0056] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(2-methyl-3-furanylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES⁺) 293. (MH⁺).

Example 12

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-imidazolylthio)propenamide]

[0057] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(2-imidazolylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compound; MS (ES⁺) 279. (MH⁺).

Example 13

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)-3-(methyl)propenamide]

[0058] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(phenylthio)-3-methylacrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compound; MS (ES⁺) 303. (MH⁺).

Example 14

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzothiazolylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-benzothiazolylthio)propenamide]

[0059] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(2-benzothiazolylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES⁺) 346. (MH⁺).

Example 15

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(1-methyl-2-imidazolylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(1-methyl-2-imidazolylthio)propenamide]

[0060] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(1-methyl-2-imidazolylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES⁺) 293. (MH⁺).

Example 16

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamide]

[0061] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(5-methyl-1,3,4-thiadiazol-2-ylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES⁺) 311. (MH⁺).

Example 17

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-chlorophenylthio)propenamide]

[0062] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(4-chlorophenylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compound; MS (ES⁺) 324,326. (MH⁺).

Example 18

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolylthio)propenamide]

[0063] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(2-thiazolylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compound; MS (ES⁺) 296. (MH⁺).

Example 19

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thienylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-thienylthio)propenamide]

[0064] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(2-thienylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES+) 295. (MH+).

Example 20

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzoxazolylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-benzoxazolylthio)propenamide]

[0065] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(2-benzoxazolylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES+) 330. (MH+).

Example 21

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-trifluoromethyl-2-pyrimidinylthio)propenamide]

[0066] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(4-trifluoromethyl-2-pyrimidinylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compound; MS (ES+) 359. (MH+).

Example 22

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-fluorophenylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-fluorophenylthio)propenamide]

[0067] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(4-fluorophenylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES+) 307. (MH+).

Example 23

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolo[4,5-b]pyridylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-thiazolo[4,5-b]pyridylthio)propenamide]

[0068] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(2-thiazolo[4,5-b]pyridylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES+) 347. (MH+).


Example 24

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-fluorophenylthio)propenamide] and (R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-fluorophenylthio)propenamide]

[0069] Employing essentially the same procedure as that described in Example 1 above but substituting 3-(3-fluorophenylthio)acrylic acid for the 3-(phenylthio)acrylic acid and purifying by chromatography on silica gel using ammoniated methanol/chloroform mixtures as the eluent resulted in formation of the title compounds; MS (ES+) 307. (MH+).





Claims

1. A compound of formula I,




wherein:

A represents:



or



R represents hydrogen or methyl;

R¹ and R² are independently hydrogen, or C₁-C₄ alkyl;

R³ and R⁴ are independently hydrogen, C₁-C₄ alkyl or SAr, provided that at least one of R³ and R⁴ represents SAr;

Ar represents a 5- or 6-membered aromatic or heteroaromatic ring containing zero to three nitrogen atoms, zero or one oxygen atom, and zero or one sulfur atom or an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atom, and zero to one sulfur atom which may optionally be substituted with one or more substituents selected from: hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, aryl, heteroaryl, -CO₂R⁵, -CN, -NO₂, -NR⁶R⁷, -CF₃, -OR⁸;

R⁵, R⁶, R⁷, and R⁸ are independently hydrogen, C₁-C₄ alkyl, aryl, heteroaryl, -C(O)R⁹, -C(O)NHR¹⁰, -C(O)R¹¹, -SO₂R¹²; or,

R⁶ and R⁷ may together be (CH₂)_jQ(CH₂)_k where Q is O, S, NR¹³, or, a bond;

j is 2 to 7;


k is 0 to 2;

R⁹, R¹⁰, R¹¹, R¹², and R¹³, are independently C₁-C₄ alkyl, aryl, or heteroaryl;

or an enantiomer thereof, and the pharmaceutically acceptable salts thereof.

2. A compound according to claim 1, wherein:

A represents:



or an enantiomer thereof, and the pharmaceutically acceptable salts thereof.

3. A compound according to claim 1, wherein R¹, R², and one of R³, R⁴ are hydrogen.
- 5 4. A compound according to claim 1, wherein Ar is a 5- or 6-membered aromatic or heteroaromatic ring containing zero to three nitrogen atoms, zero or one oxygen atom, and zero or one sulfur atom, including phenyl, 2-pyridyl, or 2-pyrimidinyl, any of which may optionally be substituted with one or more substituents selected from: hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, -CO₂R⁵, -CN, -NO₂, -NR⁶R⁷, -CF₃, -OR⁸.
- 10 5. A compound according to claim 4, wherein Ar is an heteroaromatic ring.
6. A compound according to claim 4, wherein Ar is a 6-membered aromatic or heteroaromatic ring containing zero to two nitrogen atoms.
- 15 7. A compound according to claim 1, said compound being:

N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)propenamide] hydrochloride;
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-methylphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-methylphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-methylphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-methylphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methylphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methylphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-methoxyphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-methoxyphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-methoxyphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-methoxyphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methoxyphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methoxyphenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyridylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-pyridylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-pyridylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-pyridylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyrimidinylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-pyrimidinylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methyl-3-furanylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methyl-3-furanylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-imidazolylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)-3-(methyl)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzothiazolylthio)propenamide]; *N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-benzothiazolylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(1-methyl-2-imidazolylthio)propenamide]; *N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(1-methyl-2-imidazolylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-chlorophenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thienylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-thienylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzoxazolylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-benzoxazolylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-trifluoromethyl-2-pyrimidinylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-fluorophenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-fluorophenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolo[4,5-b]pyridylthio)propenamide]; (*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-thiazolo[4,5-b]pyridylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-fluorophenylthio)propenamide];
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-fluorophenylthio)propenamide];

or an enantiomer thereof, and the pharmaceutically acceptable salts thereof.

8. A compound according to claim 1, said compound being:

(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)propenamide] hydrochloride;
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-methylphenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-methylphenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-methylphenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-methylphenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methylphenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methylphenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-methoxyphenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-methoxyphenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-methoxyphenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-methoxyphenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methoxyphenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methoxyphenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyridylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-pyridylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-pyridylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-pyridylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyrimidinylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-pyrimidinylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-methyl-3-furanylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-methyl-3-furanylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-imidazolylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)-3-(methyl)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzothiazolylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-benzothiazolylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(1-methyl-2-imidazolylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(1-methyl-2-imidazolylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-chlorophenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thienylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-thienylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzoxazolylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-benzoxazolylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-trifluoromethyl-2-pyrimidinylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(4-fluorophenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(4-fluorophenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolo[4.5-b]pyridylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-fluorophenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(3-fluorophenylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(3-fluorophenylthio)propenamide];

or an enantiomer thereof, and the pharmaceutically acceptable salts thereof.

9. A compound according to claim 1, said compound being:

(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyridylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[E-3-(2-pyridylthio)propenamide];
(*R*)-*N*-(1-Aza-bicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyrimidinylthio)propenamide];

or an enantiomer thereof, and the pharmaceutically acceptable salts thereof.


10. A compound according to any one of claims 1 to 9 for use in therapy.

EP 1 235 826 B1

11. A pharmaceutical composition including a compound as defined in any one of claims 1 to 9, in admixture with an inert pharmaceutically acceptable diluent or carrier.
12. The pharmaceutical composition according to claim 11, for use in the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders.
13. The pharmaceutical composition according to claim 11, for use in the treatment or prophylaxis of human diseases or conditions in which activation of the $\alpha 7$ nicotinic receptor is beneficial.
14. The pharmaceutical composition according to claim 11 for use in the treatment or prophylaxis of Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, Lewy Body Dementia, anxiety, schizophrenia, or mania or manic depression, Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain, or ulcerative colitis.
15. The pharmaceutical composition according to claim 11, for use in the treatment or prophylaxis of Alzheimer's disease, learning deficit, cognition deficit, attention deficit, Lewy Body Dementia, memory loss or Attention Deficit Hyperactivity Disorder.
16. The pharmaceutical composition according to claim 11, for use in the treatment or prophylaxis of anxiety, schizophrenia, or mania or manic depression.
17. The pharmaceutical composition according to claim 11, for use in the treatment or prophylaxis of Parkinson's disease, Huntington's disease, Tourette's syndrome, or neurodegenerative disorders in which there is loss of cholinergic synapses.
18. The pharmaceutical composition according to claim 11, for use in the treatment or prophylaxis of jetlag, nicotine addiction including that resulting from exposure to products containing nicotine, pain, or ulcerative colitis.
19. The pharmaceutical composition according to claim 11, for use in the treatment or prophylaxis of Alzheimer's disease.
20. Use of a compound as defined in any one of claims 1 to 9 in the manufacture of a medicament for the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders.
21. The use of a compound as defined in any one of claims 1 to 9, in the manufacture of a medicament for the treatment or prophylaxis of human diseases or conditions in which activation of the $\alpha 7$ nicotinic receptor is beneficial.
22. The use of a compound as defined in any one of claims 1 to 9, in the manufacture of a medicament for the treatment or prophylaxis of Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, Lewy Body Dementia, anxiety, schizophrenia, or mania or manic depression, Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain, or ulcerative colitis.
23. The use according to claim 22, wherein the condition or disorder is Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, or Attention Deficit Hyperactivity Disorder.
24. The use according to claim 22, wherein the disorder is anxiety, schizophrenia, or mania or manic depression.
25. The use according to claim 22, wherein the condition or disorder is jetlag, nicotine addiction including that resulting from exposure to products containing nicotine, pain, and for ulcerative colitis.

Patentansprüche


1. Verbindungen der Formel I




I

wobei:


A für



II



III



IV



V

oder



VI

steht;

R für Wasserstoff oder Methyl steht;

R¹ und R² unabhängig voneinander für Wasserstoff oder C₁-C₄-Alkyl stehen;

R³ und R⁴ unabhängig voneinander für Wasserstoff, C₁-C₄-Alkyl oder SAr stehen, mit der Maßgabe, daß wenigstens einer der Reste R³ und R⁴ für SAr steht;

Ar für einen 5- oder 6gliedrigen aromatischen oder heteroaromatischen Ring mit null bis drei Stickstoffatomen, null oder einem Sauerstoffatom und null oder einem Schwefelatom oder ein 8-, 9- oder 10gliedriges kondensiertes aromatisches oder heteroaromatisches Ringsystem mit null bis vier Stickstoffatomen, null oder einem Sauerstoffatom und null oder einem Schwefelatom steht, das gegebenenfalls durch einen oder mehrere Substituenten ausgewählt aus: Wasserstoff, Halogen, C₁-C₄-Alkyl, C₂-C₄-Alkenyl, C₂-C₄-Alkynyl, Aryl, Heteroaryl, -CO₂R⁵, -CN, -NO₂, -NR⁶R⁷, -CF₃, -OR⁸ substituiert sein kann;

R⁵, R⁶, R⁷ und R⁸ unabhängig voneinander für Wasserstoff, C₁-C₄-Alkyl, Aryl, Heteroaryl, -C(O)R⁹, -C(O)NHR¹⁰, -C(O)R¹¹, -SO₂R¹² stehen; oder

R⁶ und R⁷ zusammen für (CH₂)_jQ(CH₂)_k stehen können, wobei Q für O, S, NR¹³ oder eine Bindung steht;

j für 2 bis 7 steht;


k für 0 bis 2 steht;

R⁹, R¹⁰, R¹¹, R¹² und R¹³ unabhängig voneinander für C₁-C₄-Alkyl, Aryl oder Heteroaryl stehen;

und deren Enantiomere und deren pharmazeutisch unbedenkliche Salze.

2. Verbindungen nach Anspruch 1, wobei:

A für:



steht;

und deren Enantiomere und deren pharmazeutisch unbedenkliche Salze.

3. Verbindungen nach Anspruch 1, wobei R¹, R² und einer der Reste R³, R⁴ für Wasserstoff stehen.
4. Verbindungen nach Anspruch 1, wobei Ar für einen 5- oder 6gliedrigen aromatischen oder heteroaromatischen Ring mit null bis drei Stickstoffatomen, null oder einem Sauerstoffatom und null oder einem Schwefelatom steht, einschließlich Phenyl, 2-Pyridyl oder 2-Pyrimidinyl, die jeweils gegebenenfalls durch einen oder mehrere Substituenten ausgewählt aus: Wasserstoff, Halogen, C₁-C₄-Alkyl, C₂-C₄-Alkenyl, C₂-C₄-Alkynyl, -CO₂R⁵, -CN, -NO₂, -NR⁶R⁷, -CF₃, -OR⁸ substituiert sein können.
5. Verbindungen nach Anspruch 4, wobei Ar für einen heteroaromatischen Ring steht.
6. Verbindungen nach Anspruch 4, wobei Ar für einen 6gliedrigen aromatischen oder heteroaromatischen Ring mit null bis zwei Stickstoffatomen steht.
7. Verbindungen nach Anspruch 1, bei denen es sich um:

N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)propenamid]-hydrochlorid;
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(4-methylphenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(4-methylphenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(3-methylphenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(3-methylphenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-methylphenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-methylphenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(4-methoxyphenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(4-methoxyphenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(3-methoxyphenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(3-methoxyphenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-methoxyphenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-methoxyphenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyridylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-pyridylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(4-pyridylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(4-pyridylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyrimidinylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-pyrimidinylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-methyl-3-furanylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-methyl-3-furanylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-imidazolylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)-3-(methyl)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzothiazolylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-benzothiazolylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(1-methyl-2-imidazolylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(1-methyl-2-imidazolylthio)propenamid];

EP 1 235 826 B1

N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(4-chlorophenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-thienylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-thienylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzoxazolylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-benzoxazolylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(4-trifluormethyl-2-pyrimidinylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(4-fluorophenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(4-fluorophenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolo-[4,5-b]pyridylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-thiazolo[4,5-b]pyridylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(3-fluorophenylthio)propenamid];
N-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(3-fluorophenylthio)propenamid];

und deren Enantiomere und deren pharmazeutisch unbedenkliche Salze handelt.

8. Verbindungen nach Anspruch 1, bei denen es sich um:

(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)propenamid]-hydrochlorid;
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(4-methylphenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(4-methylphenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(3-methylphenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(3-methylphenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-methylphenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-methylphenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(4-methoxyphenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(4-methoxyphenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(3-methoxyphenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(3-methoxyphenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-methoxyphenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-methoxyphenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyridylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-pyridylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(4-pyridylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(4-pyridylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyrimidinylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-pyrimidinylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-methyl-3-furanylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-methyl-3-furanylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-imidazolylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(phenylthio)-3-(methyl)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzothiazolylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-benzothiazolylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(1-methyl-2-imidazolylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(1-methyl-2-imidazolylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(5-methyl-1,3,4-thiadiazol-2-ylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(4-chlorophenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-thienylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-thienylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-benzoxazolylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-benzoxazolylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(4-trifluormethyl-2-pyrimidinylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(4-fluorophenylthio)propenamid];
(R)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(4-fluorophenylthio)propenamid];

EP 1 235 826 B1

(*R*)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-thiazolo[4,5-*b*]pyridylthio)propenamid];
(*R*)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-thiazolo[4,5-*b*]pyridylthio)propenamid];
(*R*)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(3-fluorphenylthio)propenamid];
(*R*)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(3-fluorphenylthio)propenamid];

und deren Enantiomere und deren pharmazeutisch unbedenkliche Salze handelt.

9. Verbindungen nach Anspruch 1, bei denen es sich um:

(*R*)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyridylthio)propenamid];
(*R*)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[E-3-(2-pyridylthio)propenamid];
(*R*)-*N*-(1-Azabicyclo[2.2.2]oct-3-yl)[Z-3-(2-pyrimidinylthio)propenamid];

und deren Enantiomere und deren pharmazeutisch unbedenkliche Salze handelt.

10. Verbindungen nach einem der Ansprüche 1 bis 9 zur Verwendung in der Therapie.

11. Pharmazeutische Zusammensetzung, enthaltend eine Verbindung nach einem der Ansprüche 1 bis 9 in Abmischung mit einem inerten pharmazeutisch unbedenklichen Verdünnungsmittel oder Träger.

12. Pharmazeutische Zusammensetzung nach Anspruch 11 zur Verwendung bei der Behandlung oder Prophylaxe von psychotischen Störungen oder Intelligenzstörungen.

13. Pharmazeutische Zusammensetzung nach Anspruch 11 zur Verwendung bei der Behandlung oder Prophylaxe von Erkrankungen oder Zuständen des Menschen, bei denen die Aktivierung des nikotinischen Rezeptors $\alpha 7$ vorteilhaft ist.

14. Pharmazeutische Zusammensetzung nach Anspruch 11 zur Verwendung bei der Behandlung oder Prophylaxe von Alzheimer-Krankheit, Lernschwäche, Denkschwäche, Konzentrationsstörungen, Gedächtnisschwund, hyperkinetischem Syndrom, Lewy-Körperchen-Demenz, Angst, Schizophrenie, Manie oder manischer Depression, Parkinson-Krankheit, Chorea Huntington, Tourette-Syndrom, neurodegenerativen Erkrankungen mit Verlust cholinergischer Synapsen, Jet-lag, Raucherentwöhnung, Nikotinabhängigkeit einschließlich der sich aus der Exposition gegenüber nikotinhaltenen Produkten ergebenden Abhängigkeit, Schmerzen oder Colitis ulcerosa.

15. Pharmazeutische Zusammensetzung nach Anspruch 11 zur Verwendung bei der Behandlung oder Prophylaxe von Alzheimer-Krankheit, Lernschwäche, Denkschwäche, Konzentrationsstörungen, Lewy-Körperchen-Demenz, Gedächtnisschwund oder hyperkinetischem Syndrom.

16. Pharmazeutische Zusammensetzung nach Anspruch 11 zur Verwendung bei der Behandlung oder Prophylaxe von Angst, Schizophrenie, Manie oder manischer Depression.

17. Pharmazeutische Zusammensetzung nach Anspruch 11 zur Verwendung bei der Behandlung oder Prophylaxe von Parkinson-Krankheit, Chorea Huntington, Tourette-Syndrom oder neurodegenerativen Erkrankungen mit Verlust cholinergischer Synapsen.

18. Pharmazeutische Zusammensetzung nach Anspruch 11 zur Verwendung bei der Behandlung oder Prophylaxe von Jet-lag, Nikotinabhängigkeit einschließlich der sich aus der Exposition gegenüber nikotinhaltenen Produkten ergebenden Abhängigkeit, Schmerzen oder Colitis ulcerosa.

19. Pharmazeutische Zusammensetzung nach Anspruch 11 zur Verwendung bei der Behandlung oder Prophylaxe von Alzheimer-Krankheit.


20. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 9 bei der Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von psychotischen Störungen oder Intelligenzstörungen.

21. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 9 bei der Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von Erkrankungen oder Zuständen des Menschen, bei denen die Aktivierung des nikotinischen Rezeptors $\alpha 7$ vorteilhaft ist.

22. Utilisation d'une Verbindung nach einem der Ansprüche 1 bis 9 bei der Herstellung eines Arzneimittels zur Behandlung oder Prophylaxe von Alzheimer-Krankheit, Lernschwäche, Denkschwäche, Konzentrationsstörungen, Gedächtnisschwund, hyperkinetischem Syndrom, Lewy-Körperchen-Demenz, Angst, Schizophrenie, Manie oder manischer Depression, Parkinson-Krankheit, Chorea Huntington, Tourette-Syndrom, neurodegenerativen Erkrankungen mit Verlust cholinergischer Synapsen, Jet-lag, Raucherentwöhnung, Nikotinabhängigkeit einschließlich der sich aus der Exposition gegenüber nikotinhaltigen Produkten ergebenden Abhängigkeit, Schmerzen oder Colitis ulcerosa.
23. Utilisation nach Anspruch 22, wobei es sich bei dem Zustand oder der Erkrankung um Alzheimer-Krankheit, Lernschwäche, Denkschwäche, Konzentrationsstörungen, Gedächtnisschwund, Lewy-Körperchen-Demenz, oder hyperkinetisches Syndrom handelt.
24. Utilisation nach Anspruch 22, wobei es sich bei der Erkrankung um Angst, Schizophrenie, Manie oder manische Depression handelt.
25. Utilisation nach Anspruch 22, wobei es sich bei dem Zustand oder der Erkrankung um Jet-lag, Nikotinabhängigkeit einschließlich der sich aus der Exposition gegenüber nikotinhaltigen Produkten ergebenden Abhängigkeit, Schmerzen oder Colitis ulcerosa handelt.





Revendications

1. Composé de formule I,




dans laquelle :

A représente :



or



R représente un atome d'hydrogène ou un groupe méthyle;

R¹ et R² sont, indépendamment l'un de l'autre, un atome d'hydrogène ou un groupe alkyle en C₁-C₄;

R³ et R⁴ sont, indépendamment l'un de l'autre, un atome d'hydrogène ou un groupe alkyle en C₁-C₄ ou SAR, à condition que l'un au moins des radicaux R³ et R⁴ représente SAR;

Ar représente un noyau aromatique ou hétéroaromatique à 5 ou 6 chaînons contenant zéro à trois atomes d'azote, zéro ou un atome d'oxygène, et zéro ou un atome de soufre ou un système de noyaux aromatiques ou hétéro-aromatiques condensés à 8, 9 ou 10 chaînons contenant zéro à quatre atomes d'azote, zéro à un atome d'oxygène et zéro à un atome de soufre qui peut éventuellement être substitué par un ou plusieurs substituants choisis parmi : les atomes d'hydrogène, d'halogène et les groupes alkyle en C₁-C₄, alcényle en C₂-C₄, alcynyle en C₂-C₄, aryle, hétéroaryle, -CO₂R⁵, -CN, -NO₂, -NR⁶R⁷, -CF₃, -OR⁸;

R⁵, R⁶, R⁷ et R⁸ sont, indépendamment les uns des autres, un atome d'hydrogène ou un groupe alkyle en C₁-C₄, aryle, hétéroaryle, -C(O)R⁹, -C(O)NHR¹⁰, -C(O)R¹¹, -SO₂R¹²; ou

R⁶ et R⁷ peuvent être ensemble (CH₂)_jQ(CH₂)_k où Q est O, S, NR¹³, ou une liaison;

j vaut 2 à 7;


k vaut 0 à 2;

R⁹, R¹⁰, R¹¹, R¹² et R¹³ sont, indépendamment les uns des autres, des groupes alkyle en C₁-C₄, aryle ou hétéroaryle;

ou un énantiomère de ce composé, et les sels pharmaceutiquement acceptables de ce composé.

2. Composé selon la revendication 1, dans lequel :

A représente :



ou un énantiomère de ce composé, et les sels pharmaceutiquement acceptables de ce composé.

3. Composé selon la revendication 1, dans lequel R¹, R² et un des radicaux R³ et R⁴ sont des atomes d'hydrogène.

4. Composé selon la revendication 1, dans lequel Ar est un noyau aromatique ou hétéroaromatique à 5 ou 6 chaînons contenant zéro à trois atomes d'azote, zéro ou un atome d'oxygène et zéro ou un atome de soufre, notamment phényle, 2-pyridyle ou 2-pyrimidinyle, l'un quelconque d'entre eux pouvant éventuellement être substitué par un ou plusieurs substituants choisis parmi : un atome d'hydrogène ou d'halogène, ou un groupe alkyle en C₁-C₄, alcényle en C₂-C₄, alcynyle en C₂-C₄, -CO₂R⁵, -CN, -NO₂, -NR⁶R⁷, -CF₃, -OR⁸.

5. Composé selon la revendication 4, dans lequel Ar est un noyau hétéroaromatique.

6. Composé selon la revendication 4, dans lequel Ar est un noyau aromatique ou hétéroaromatique à 6 chaînons contenant zéro à deux atomes d'azote.

7. Composé selon la revendication 1, ledit composé étant :

le chlorhydrate de N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(phénylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(4-méthyl-phénylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(4-méthyl-phénylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(3-méthyl-phénylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(3-méthyl-phénylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-méthyl-phénylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-méthyl-phénylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(4-méthoxy-phénylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(4-méthoxy-phénylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(3-méthoxy-phénylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(3-méthoxy-phénylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-méthoxy-phénylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-méthoxy-phénylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-pyridylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-pyridylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(4-pyridylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(4-pyridylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-pyrimidinylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-pyrimidinylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-méthyl-3-furanylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-méthyl-3-furanylthio)propénamide];

le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-imidazolylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(phénylthio)-3-(méthyl)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-benzothiazolylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-benzothiazolylthio)propénamide];
 5 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[2-3-(1-méthyl-2-imidazolylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(1-méthyl-2-imidazolylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(5-méthyl-1,3,4-thiadiazol-2-ylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(5-méthyl-1,3,4-thiadiazol-2-ylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(4-chlorophénylthio)propénamide];
 10 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-thiazolylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-thiénylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-thiénylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-benzoxazolylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-benzoxazolylthio)propénamide];
 15 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(4-trifluorométhyl-2-pyrimidinylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(4-fluorophénylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(4-fluorophénylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-thiazolo-[4,5-b]pyridylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-thiazolo-[4,5-b]pyridylthio)propénamide];
 20 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(3-fluorophénylthio)propénamide];
 le N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(3-fluorophénylthio)propénamide];

ou un énantiomère de ce composé, et les sels pharmaceutiquement acceptables de ce composé.

8. Composé selon la revendication 1, ledit composé étant :

le chlorhydrate de (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(phénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(4-méthyl-phénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(4-méthyl-phénylthio)propénamide];
 30 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(3-méthyl-phénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(3-méthyl-phénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-méthyl-phénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-méthyl-phénylthio)propénamide];
 35 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(4-méthoxy-phénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(4-méthoxy-phénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(3-méthoxy-phénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(3-méthoxy-phénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-méthoxy-phénylthio)propénamide];
 40 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-méthoxy-phénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-pyridyl-thio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-pyridylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(4-pyridylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(4-pyridylthio)propénamide];
 45 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-pyrimidinylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-pyrimidinylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-méthyl-3-furanylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-méthyl-3-furanylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-imidazolylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(phénylthio)-3-(méthyl)propénamide];
 50 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-benzothiazolylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-benzothiazolylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(1-méthyl-2-imidazolylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(1-méthyl-2-imidazolylthio)propénamide];
 55 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(5-méthyl-1,3,4-thiadiazol-2-ylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(5-méthyl-1,3,4-thiadiazol-2-ylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(4-chlorophénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-thiazolylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-thiénylthio)propénamide];

le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-thiénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-benzoxazolylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-benzoxazolylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(4-trifluorométhyl-2-pyrimidinylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(4-fluorophénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(4-fluorophénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-thiazolo[4,5-b]pyridylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-thiazolo[4,5-b]pyridylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(3-fluorophénylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(3-fluorophénylthio)propénamide];

ou un énantiomère de ce composé, et les sels pharmaceutiquement acceptables de ce composé.

9. Composé selon la revendication 1, ledit composé étant :

le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-pyridylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[E-3-(2-pyridylthio)propénamide];
 le (R)-N-(1-aza-bicyclo[2,2,2]oct-3-yl)[Z-3-(2-pyrimidinylthio)propénamide];

ou un énantiomère de ce composé, et les sels pharmaceutiquement acceptables de ce composé.

10. Composé selon l'une quelconque des revendications 1 à 9 à utiliser en thérapeutique.

11. Composition pharmaceutique renfermant un composé tel que défini dans l'une quelconque des revendications 1 à 9, en mélange avec un diluant ou un véhicule pharmaceutiquement acceptable inerte.

12. Composition pharmaceutique selon la revendication 11 à utiliser dans le traitement ou la prophylaxie de troubles psychotiques ou de troubles de détérioration mentale.

13. Composition pharmaceutique selon la revendication 11 à utiliser dans le traitement ou la prophylaxie de maladies ou d'affections humaines dans lesquelles l'activation du récepteur $\alpha 7$ -nicotinique est bénéfique.

14. Composition pharmaceutique selon la revendication 11 à utiliser dans le traitement ou la prophylaxie de la maladie d'Alzheimer, de la difficulté d'apprentissage, du déficit cognitif, du défaut d'attention, de la perte de mémoire, du trouble déficitaire de l'attention avec hyperactivité, de la démence à corps de Lewy, de l'anxiété, de la schizophrénie ou des manies ou de la dépression maniaque, de la maladie de Parkinson, de la maladie d'Huntington, du syndrome de Tourette, des troubles neurodégénératifs dans lesquels il y a une perte de la synapse cholinergique, des troubles dus au décalage horaire, de l'arrêt du tabac, de la dépendance à la nicotine, notamment de celle qui résulte de l'exposition à des produits contenant de la nicotine, de la douleur ou de la rectocolite hémorragique.

15. Composition pharmaceutique selon la revendication 11 à utiliser dans le traitement ou la prophylaxie de la maladie d'Alzheimer, de la difficulté d'apprentissage, du déficit cognitif, du défaut d'attention, de la démence à corps de Lewy, de la perte de mémoire ou du trouble déficitaire de l'attention avec hyperactivité.

16. Composition pharmaceutique selon la revendication 11 à utiliser dans le traitement ou la prophylaxie de l'anxiété, de la schizophrénie, ou des manies ou de la dépression maniaque.

17. Composition pharmaceutique selon la revendication 11 à utiliser dans le traitement ou la prophylaxie de la maladie de Parkinson, de la maladie d'Huntington, du syndrome de Tourette, ou des troubles neurodégénératifs dans lesquels il y a une perte de la synapse cholinergique.

18. Composition pharmaceutique selon la revendication 11 à utiliser dans le traitement ou la prophylaxie des troubles dus au décalage horaire, de la dépendance à la nicotine, notamment de celle qui résulte de l'exposition à des produits contenant de la nicotine, de la douleur ou de la rectocolite hémorragique.

19. Composition pharmaceutique selon la revendication 11 à utiliser dans le traitement ou la prophylaxie de la maladie d'Alzheimer.

EP 1 235 826 B1

20. Utilisation d'un composé tel que défini dans l'une quelconque des revendications 1 à 9 dans la fabrication d'un médicament destiné au traitement ou à la prophylaxie de troubles psychotiques ou de troubles de détérioration mentale.

21. Utilisation d'un composé tel que défini dans l'une quelconque des revendications 1 à 9 dans la fabrication d'un médicament destiné au traitement ou à la prophylaxie de maladies ou d'affections humaines dans lesquelles l'activation du récepteur $\alpha 7$ -nicotinique est bénéfique.

22. Utilisation d'un composé tel que défini dans l'une quelconque des revendications 1 à 9 dans la fabrication d'un médicament destiné au traitement ou à la prophylaxie de la maladie d'Alzheimer, de la difficulté d'apprentissage, du déficit cognitif, du défaut d'attention, de la perte de mémoire, du trouble déficitaire de l'attention avec hyperactivité, de la démence à corps de Lewy, de l'anxiété, de la schizophrénie ou des manies ou de la dépression maniaque, de la maladie de Parkinson, de la maladie d'Huntington, du syndrome de Tourette, des troubles neurodégénératifs dans lesquels il y a une perte de la synapse cholinergique, des troubles dus au décalage horaire, de l'arrêt du tabac, de la dépendance à la nicotine, notamment de celle qui résulte de l'exposition à des produits contenant de la nicotine, de la douleur ou de la rectocolite hémorragique.

23. Utilisation selon la revendication 22, dans laquelle la maladie ou l'affection est la maladie d'Alzheimer, la difficulté d'apprentissage, le déficit cognitif, le défaut d'attention, la perte de mémoire, la démence à corps de Lewy ou le trouble déficitaire de l'attention avec hyperactivité.

24. Utilisation selon la revendication 22, dans laquelle l'affection est l'anxiété, la schizophrénie ou les manies ou la dépression maniaque.

25. Utilisation selon la revendication 22, dans laquelle la maladie ou l'affection est le trouble dû au décalage horaire, la dépendance à la nicotine, notamment celle qui résulte de l'exposition à des produits contenant de la nicotine, la douleur et la rectocolite hémorragique.